Christian Alvarez

Dr. Christian Alvarez

National Cancer Institute
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
AFAndrea A. Florio
Andrea A. Florio
JFJacques Ferlay
Jacques Ferlay
AZAriana Znaor
Ariana Znaor
DRDavid Ruggieri
David Ruggieri
CAChristian Alvarez
Christian Alvarez
JPJessica L. Petrick
Jessica L. Petrick

16 November 2019 in Hepatology
Verified
Journal Article
Open access
PDF file
CAChristian Alvarez
Christian Alvarez
BGBarry I. Graubard
Barry I. Graubard
JTJake E. Thistle
Jake E. Thistle
JPJessica L. Petrick
Jessica L. Petrick
KMKatherine A. McGlynn
Katherine A. McGlynn
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) encompasses a range of conditions, from simple steatosis to nonalcoholic steatohepatitis. Studies in the United States have reported an increased mortality risk among individuals with NAFLD; therefore, the population attributable fractions (PAFs) for mortality were examined. Approach and Results: A total of 12,253 adult individuals with ultrasound assessment of NAFLD from the Third National Health and Nutrition Examination Survey and mortality follow‐up through 2015 were included in the analysis. Cox proportional hazard regression was used to estimate multivariable‐adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for NAFLD in association with all‐cause and cause‐specific mortality. Overall, sex‐ and race/ethnicity‐specific PAFs and 95% CIs were estimated. In the current study, presence of NAFLD was associated with a 20% increased risk of all‐cause mortality (HR, 1.20; 95% CI, 1.08, 1.34). The overall PAF for all‐cause mortality associated with NAFLD was 7.5% (95% CI, 3.0, 12.0). The PAF for diabetes‐specific mortality was 38.0% (95% CI, 13.1, 63.0) overall, 40.8% (95% CI, 2.1, 79.6) in men, and 36.8% (95% CI, 6.6, 67.0) in women. The PAF for liver disease (LD)‐specific mortality was notably higher in men (68.3%; 95% CI, 36.3, 100.0) than women (3.5%; 95% CI, −39.7, 46.8). In the race‐specific analysis, the PAFs of NAFLD for all‐cause mortality (9.3%; 95% CI, 4.0, 14.6) and diabetes‐specific mortality (44.4%; 95% CI, 10.8, 78.0) were significantly greater than zero only for whites. Conclusions: In the United States, approximately 8% of all‐cause mortality and more than one‐third of LD‐ and diabetes‐specific deaths are associated with NAFLD. With these high percentages, efforts are needed to reduce the burden of NAFLD in the United States.

22 April 2022 in Hepatology
Verified
Journal Article
Closed access
CAChristian Alvarez
Christian Alvarez
JPJessica L. Petrick
Jessica L. Petrick
DPDominick Parisi
Dominick Parisi
BMBrian J. McMahon
Brian J. McMahon
BGBarry I. Graubard
Barry I. Graubard
KMKatherine McGlynn
Katherine McGlynn

7 April 2021 in World Mycotoxin Journal
Verified
Journal Article
Open access
JGJohn D. Groopman
John D. Groopman
JSJoshua Smith
Joshua Smith
ARA. Rivera-Andrade
A. Rivera-Andrade
CAChristian Alvarez
Christian Alvarez
MKM.F. Kroker-Lobos
M.F. Kroker-Lobos
MRManuel Ramirez-Zea
Manuel Ramirez-Zea
During the 60 years since the first scientific reports about a relation between aflatoxin exposure and adverse health consequences, both in animals and humans, there has been a remarkable number of basic, clinical and population science studies characterising the impact of this mycotoxin on diseases such as liver cancer. Many of these human investigations to date have focused on populations residing in Asia and Africa due to the high incidence of liver cancer and high exposures to aflatoxin. These studies formed the basis for the International Agency for Research on Cancer to classify the aflatoxins as Group 1 known human carcinogens. In addition, aflatoxin contamination levels have been used in international commodity trade to set the price of various staples such as maize and groundnuts. While there have been many case-control and prospective cohort studies of liver cancer risk over the years there have been remarkably few investigations focused on liver cancer in Latin America. Our interdisciplinary and multiple institutional collaborative has been developing a long-term strategy to characterise the role of aflatoxin and other mycotoxins as health risk factors in Guatemala and neighbouring countries. This paper summarises a number of the investigations to date and provides a roadmap of our strategies for the near term to discern the emergent aetiology of liver cancer in this region. With these data in hand public health-based prevention strategies could be strategically implemented and conducted to lower the impact of these mycotoxins on human health.

28 July 2023 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JTJ. Smith Torres-Roman
J. Smith Torres-Roman
JYJorge Ybaseta-Medina
Jorge Ybaseta-Medina
SLSilvana Loli-Guevara
Silvana Loli-Guevara
JBJanina Bazalar-Palacios
Janina Bazalar-Palacios
BVBryan Valcarcel
Bryan Valcarcel
YHYamilee Hurtado-Roca
Yamilee Hurtado-Roca
Background: Breast cancer is among the leading cause of cancer-related mortality among Latin American and Caribbean (LAC) women, but a comprehensive and updated analysis of mortality trends is lacking. The objective of this study was to determine the breast cancer mortality rates between 1997 and 2017 for LAC countries and predict mortality until 2030. Methods: We retrieved breast cancer deaths across 17 LAC countries from the World Health Organization mortality database. Age-standardized mortality rates per 100,000 women-years were estimated. Mortality trends were evaluated with Joinpoint regression analyses by country and age group (all ages, < 50 years, and ≥ 50 years). By 2030, we predict number of deaths, mortality rates, changes in population structure and size, and the risk of death from breast cancer. Results: Argentina, Uruguay, and Venezuela reported the highest mortality rates throughout the study period. Guatemala, El Salvador, and Nicaragua reported the largest increases (from 2.4 to 2.8% annually), whereas Argentina, Chile, and Uruguay reported downward trends (from − 1.0 to − 1.6% annually). In women < 50y, six countries presented downward trends and five countries showed increasing trends. In women ≥ 50y, three countries had decreased trends and ten showed increased trends. In 2030, increases in mortality are expected in the LAC region, mainly in Guatemala (+ 63.0%), Nicaragua (+ 47.3), El Salvador (+ 46.2%), Ecuador (+ 38.5%) and Venezuela (+ 29.9%). Conclusion: Our findings suggest considerable differences in breast cancer mortality across LAC countries by age group. To achieve the 2030 sustainable developmental goals, LAC countries should implement public health strategies to reduce mortality by breast cancer.

2 October 2020 in Helicobacter
Verified
Journal Article
Closed access
CAChristian Alvarez
Christian Alvarez
AFAndrea A. Florio
Andrea A. Florio
JBJulia Butt
Julia Butt
ARAlvaro Rivera‐Andrade
Alvaro Rivera‐Andrade
MKMaría F. Kroker‐Lobos
María F. Kroker‐Lobos
KMKatherine A. McGlynn
Katherine A. McGlynn